PURPOSE: To compare lengths of in-hospital stay (LOS) and costs for patients with community-acquired pneumonia (CAP) treated with intravenous moxifloxacin 400 mg or levofloxacin 750 mg.
METHODS: Premier PerspectiveÖ Comparative Database data were analyzed for adult patients hospitalized with CAP and treated for ≥3 days with moxifloxacin 400 mg or levofloxacin 750 mg, from April 2003 to March 2006, and who had no prior-year CAP admission. Data were analyzed for all patients meeting inclusion/exclusion criteria; data for treatment groups were propensity-score matched to reduce any bias from potential confounding factors.
RESULTS: Unmatched groups comprised 6,040 patients who received moxifloxacin 400 mg and 1,680 who received levofloxacin 750 mg and met the other inclusion/exclusion criteria. The two matched groups of 1,300 patients each were well balanced for patient, payor, hospital, physician, and disease characteristics (P>0.2 for each characteristic; P=0.986 for age and P=0.270 for disease severity). The matched groups were not statistically different from each other in mean LOS or total hospital cost: mean LOS was 5.6±3.5 days for the moxifloxacin 400-mg group and 5.5±3.5 days for the levofloxacin 750-mg group (P=0.462); mean total hospital cost was $6,624±$5,576 for the moxifloxacin 400-mg group and $6,473±$4,782 for the levofloxacin 750-mg group (P=0.476). For both groups, costs for room and board constituted >50% of total costs.
CONCLUSION: There was no statistically significant difference in either LOS or hospital costs between propensity-score matched groups of CAP patients treated with moxifloxacin 400 mg or levofloxacin 750 mg.
CLINICAL IMPLICATIONS: In-hospital treatment of CAP with intravenous moxifloxacin 400 mg or levofloxacin 750 mg is associated with similar LOS and hospital costs.
DISCLOSURE: Prakash Navaratnam, Grant monies (from industry related sources) This study and its report were supported by Schering-Plough Pharmaceuticals, Kenilworth, NJ. Prakash Navaratnam is an employee of Informagenics, LLC (Worthington, OH), and Howard Friedman of Analytical Solutions, LLC (New York, NY). Xue Song is an employee of Thomson Reuters (New York, NY). All three companies provide consultation with the pharmaceutical industry, and both Drs. Navaratnam and Friedman were remunerated by the study sponsor. Simone Crespi is an employee of the study sponsor.; No Product/Research Disclosure Information